{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:02:26Z","timestamp":1793779346589,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, widely used for type 2 diabetes and cardiorenal conditions, may induce erythrocytosis, potentially increasing cardiovascular risk. This study investigates its prevalence, risk factors, and thrombotic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a single-center retrospective study, we analyzed 6787 patients prescribed SGLT-2 inhibitors (2014\u20132024). Erythrocytosis was defined as hemoglobin\u2009&gt;\u200916.5\u00a0g\/dL or hematocrit\u2009&gt;\u200949% in men,\u2009&gt;\u200916.0\u00a0g\/dL or\u2009&gt;\u200948% in women. We assessed prevalence, risk factors, and thrombotic events using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Erythrocytosis occurred in 1145 patients (16.9%) over a median follow-up of 530\u00a0days (IQR, 277\u2013981), with a median hemoglobin rise of 1.0\u00a0g\/dL (IQR, 0.4\u20131.8). Male sex (OR 3.24, 95% CI 2.47\u20134.26), BMI\u2009\u2265\u200925\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (OR 1.97, 95% CI 1.63\u20132.39), and current smoking (OR 2.41, 95% CI 1.96\u20132.96) significantly increased risk (all p\u2009&lt;\u20090.001), while age\u2009\u2265\u200970\u00a0years, hypertension, dyslipidemia, and chronic kidney disease were associated with reduced risk. Thrombosis was rare (0.5%, 33 patients) and associated with antiplatelet use (OR 3.57, 95% CI 1.60\u20137.97), anticoagulant use (OR 5.93, 95% CI 2.60\u201313.57), and baseline erythrocytosis (OR 3.75, 95% CI 1.41\u20139.96). Among 33 patients with thrombosis, five exhibited erythrocytosis at the time of the event and within the prior six months; all had arterial thrombosis associated with underlying conditions (atrial fibrillation, coronary calcification, atherosclerosis), not directly attributable to SGLT-2-induced erythrocytosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SGLT-2 inhibitors are associated with a 16.9% prevalence of erythrocytosis, but thrombotic risk appears primarily driven by pre-existing conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-02805-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:08:19Z","timestamp":1752138499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Ji Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woochan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"6","key":"2805_CR1","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"HU H\u00e4ring","year":"2014","unstructured":"HU H\u00e4ring L Merker E Seewaldt-Becker M Weimer T Meinicke UC Broedl 2014 Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 6 1650 1659","journal-title":"Diabetes Care"},{"issue":"22","key":"2805_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B Zinman C Wanner JM Lachin D Fitchett E Bluhmki S Hantel 2015 Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 22 2117 2128","journal-title":"N Engl J Med"},{"issue":"15","key":"2805_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"HJL Heerspink BV Stef\u00e1nsson R Correa-Rotter GM Chertow T Greene FF Hou 2020 Dapagliflozin in patients with chronic kidney disease N Engl J Med 383 15 1436 1446","journal-title":"N Engl J Med"},{"issue":"10","key":"2805_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"L Blonde GE Umpierrez SS Reddy JB McGill SL Berga M Bush 2022 American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update Endocr Pract 28 10 923 1049","journal-title":"Endocr Pract"},{"issue":"9","key":"2805_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"R Adhikari K Jha Z Dardari J Heyward RS Blumenthal RH Eckel 2022 National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020 J Am Heart Assoc 11 9 e023811","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2805_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s13340-022-00577-y","volume":"13","author":"H Takahashi","year":"2022","unstructured":"H Takahashi Y Suganuma T Ohno R Nishimura 2022 Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus Diabetol Int 13 4 606 614","journal-title":"Diabetol Int"},{"issue":"2","key":"2805_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/jdi.14363","volume":"16","author":"KH Ha","year":"2025","unstructured":"KH Ha S Shin E Na DJ Kim 2025 Trends in prescribing sodium-glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular-renal disease in South Korea, 2015\u20132021 J Diabetes Investig 16 2 215 224","journal-title":"J Diabetes Investig"},{"key":"2805_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108127","volume":"162","author":"R Gupta","year":"2020","unstructured":"R Gupta A Gupta M Shrikhande K Tyagi A Ghosh A Misra 2020 Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases Diabetes Res Clin Pract 162 108127","journal-title":"Diabetes Res Clin Pract"},{"issue":"42","key":"2805_CR9","doi-asserted-by":"publisher","first-page":"E1271","DOI":"10.1503\/cmaj.76686","volume":"192","author":"B Chin-Yee","year":"2020","unstructured":"B Chin-Yee Z Solh C Hsia 2020 Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors CMAJ 192 42 E1271","journal-title":"CMAJ"},{"issue":"26","key":"2805_CR10","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood.2021013996","volume":"138","author":"N Gangat","year":"2021","unstructured":"N Gangat N Szuber H Alkhateeb A Al-Kali A Pardanani A Tefferi 2021 JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy Blood 138 26 2886 2889","journal-title":"Blood"},{"issue":"7","key":"2805_CR11","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.1002\/ajh.26933","volume":"98","author":"N Gangat","year":"2023","unstructured":"N Gangat M Abdallah N Szuber A Saliba H Alkhateeb A Al-Kali 2023 Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases Am J Hematol 98 7 E165 E167","journal-title":"Am J Hematol"},{"issue":"6","key":"2805_CR12","doi-asserted-by":"publisher","first-page":"2300049","DOI":"10.1056\/EVIDoa2300049","volume":"2","author":"A Koshino","year":"2023","unstructured":"A Koshino M Schechter GM Chertow P Vart N Jongs RD Toto 2023 Dapagliflozin and anemia in patients with chronic kidney disease NEJM Evid. 2 6 2300049","journal-title":"NEJM Evid."},{"issue":"1","key":"2805_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/joim.13722","volume":"295","author":"J Liu","year":"2024","unstructured":"J Liu B Chin-Yee IH Chin-Yee J Ho B Sadikovic CC Hsia 2024 Sodium-glucose cotransporter-2 inhibitor-associated erythrocytosis: a retrospective cohort study J Intern Med 295 1 103 105","journal-title":"J Intern Med"},{"issue":"2","key":"2805_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"C Wanner JM Lachin SE Inzucchi D Fitchett M Mattheus J George 2018 Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease Circulation 137 2 119 129","journal-title":"Circulation"},{"issue":"9","key":"2805_CR15","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1182\/bloodadvances.2024015410","volume":"9","author":"J Liu","year":"2025","unstructured":"J Liu B Chin-Yee J Ho A Lazo-Langner IH Chin-Yee A Iansavitchene 2025 Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review Blood Adv 9 9 2108 2118","journal-title":"Blood Adv"},{"key":"2805_CR16","doi-asserted-by":"crossref","unstructured":"Doi Y, Hamano T, Yamaguchi O, Isaka Y. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. Blood Adv. 2025.","DOI":"10.1182\/bloodadvances.2025016320"},{"key":"2805_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.630820","volume":"12","author":"W Qu","year":"2021","unstructured":"W Qu L Yao X Liu T Xu B Tian 2021 Effects of sodium-glucose co-transporter 2 inhibitors on hemoglobin levels: a meta-analysis of randomized controlled trials Front Pharmacol 12 630820","journal-title":"Front Pharmacol"},{"issue":"2","key":"2805_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"KM Talha SD Anker J Butler 2023 SGLT-2 inhibitors in heart failure: a review of current evidence Int J Heart Fail 5 2 82 90","journal-title":"Int J Heart Fail"},{"key":"2805_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portol\u00e9s","year":"2021","unstructured":"J Portol\u00e9s L Mart\u00edn JJ Broseta A Cases 2021 Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents Front Med 8 642296","journal-title":"Front Med"},{"issue":"10","key":"2805_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s11606-024-08640-x","volume":"39","author":"MCH Lassen","year":"2024","unstructured":"MCH Lassen M Colacci M Pareek SG Lee G Gislason M Fralick 2024 Association between SGLT2 inhibitor use and change in hemoglobin among adults with diabetes: a nationwide cohort study J Gen Intern Med 39 10 1945 1947","journal-title":"J Gen Intern Med"},{"issue":"4","key":"2805_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","volume":"11","author":"E Nguyen","year":"2021","unstructured":"E Nguyen M Harnois L Busque S Sirhan S Assouline I Chamaki 2021 Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera Blood Cancer J 11 4 75","journal-title":"Blood Cancer J"},{"issue":"14","key":"2805_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037751","volume":"103","author":"FD Koseoglu","year":"2024","unstructured":"FD Koseoglu F Keklik Karadag H Bulbul EU Alici B Ozyilmaz TR Ozdemir 2024 JAKCalc: a machine-learning approach to rationalized JAK2 testing in patients with elevated hemoglobin levels Medicine 103 14 e37751","journal-title":"Medicine"},{"issue":"10","key":"2805_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"G Weiss LT Goodnough 2005 Anemia of chronic disease N Engl J Med 352 10 1011 1023","journal-title":"N Engl J Med"},{"issue":"2","key":"2805_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1183\/09031936.06.00143704","volume":"27","author":"T Similowski","year":"2006","unstructured":"T Similowski A Agust\u00ed W MacNee B Sch\u00f6nhofer 2006 The potential impact of anaemia of chronic disease in COPD Eur Respir J 27 2 390 396","journal-title":"Eur Respir J"},{"issue":"4","key":"2805_CR25","first-page":"391","volume":"16","author":"V Vlahakos","year":"2022","unstructured":"V Vlahakos K Marathias S Lionaki S Loukides S Zakynthinos D Vlahakos 2022 The paradigm shift from polycythemia to anemia in COPD: the critical role of the renin-angiotensin system inhibitors Expert Rev Respir Med 16 4 391 398","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"2805_CR26","volume":"15","author":"S Tariq","year":"2023","unstructured":"S Tariq D Ismail M Thapa L Goriparthi R Pradeep K Khalid 2023 Chronic obstructive pulmonary disease and its effect on red blood cell indices Cureus 15 3 e36100","journal-title":"Cureus"},{"issue":"6","key":"2805_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/ajh.26920","volume":"98","author":"N Gangat","year":"2023","unstructured":"N Gangat N Szuber A Tefferi 2023 JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management Am J Hematol 98 6 965 981","journal-title":"Am J Hematol"},{"issue":"24","key":"2805_CR28","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","volume":"4","author":"H Wouters","year":"2020","unstructured":"H Wouters R Mulder IA Zeventer van JJ Schuringa MM Klauw van der P Harst van der 2020 Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis Blood Adv 4 24 6353 6363","journal-title":"Blood Adv"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02805-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:27:42Z","timestamp":1757219262000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02805-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02805-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (IRB No. B-2404-892-402). The need for patient consent was waived by the IRB due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}